powerwalker, thanks. Yes, it reads better. The structural sequences and (shall/may) delivery is till inconsistent w/today's needs and technological capability/style. Overall, if sponsors must wait they are going to be looking elsewhere. IMO, if AVXL gets results by going a different path the FDA will have to adapt instead of insisting that everyone else follow them. IMO.
News 
Market Data 
Discover 
